Podcasts about Sanofi

Transplantation can save lives. So why do patients who could benefit still face so many barriers to receiving one?The science and clinical capabilities of transplantation have advanced dramatically, yet the patient journey remains extraordinarily complex. From understanding transplant options and getting referred to the right center to navigating insurance, organ availability, policy changes, and a complicated healthcare system, patients can encounter friction at nearly every step. Underlying many of these challenges is something even more fundamental: trust.In this episode, host Eric Racine, PharmD, and co-host Kemi Osundina-Mkhize, PharmD, of Sanofi are joined by Henry Randall, MD, President of the American Society of Transplant Surgeons (ASTS). Together, they explore where patients are getting stuck in the transplant system and how clinicians, professional societies, patient advocates, policymakers, and other stakeholders can work together to improve access, build trust, and improve the patient experience.Dr. Randall shares how ASTS works to elevate patients' voices, advance transplant access, strengthen health literacy, address misinformation, and prepare for policy changes and emerging technologies that could shape the future of transplantation.In this episode, you'll learn about:Ways that patient advocacy and stakeholder collaboration can improve access and help patients navigate a changing transplant systemHow evidence-based communication, health literacy, and trusted messengers can build trustWhy listening to patients is only the first step toward meaningful changeWhy patient advocates need a seat at the table as AI and other technologies transform transplantationA leadership lesson for advocacy professionals: listen across disciplines and bring diverse perspectives togetherThis conversation is a reminder that scientific innovation alone does not guarantee patient access. Progress also depends on reducing system friction, earning trust, listening to patients, and turning their experiences into meaningful action.

"If you are looking for perfection, you will never try anything new." "Their ownership is crucial because they are outstanding at implementing it." "Longevity matters. There is a very direct correlation to trust." "If it does not work, it is a risk that I take along with you." "Your job is not to impress me. Your role is to do the best for the organisation."   Nikhilesh Kalra is President of SSP Co., Ltd., a 260-year-old Japanese healthcare company now part of Opella. SSP is best known through its portfolio of branded over-the-counter medicines, including EVE, a market-leading pain-relief brand, as well as products for allergies and colds. The company began as a family business, later became publicly listed and progressively focused its portfolio on consumer healthcare before becoming wholly owned by multinational groups. Kalra built his career in multinational healthcare businesses and worked across several Asian markets and the United Kingdom. He was serving in a Sanofi role in India when he was asked to lead SSP in Japan in 2022. He subsequently guided the organisation through the carve-out of Sanofi's consumer healthcare business into the independent Opella group. His leadership experience in Japan centres on modernising a deeply established company without discarding its history, increasing risk appetite while protecting pharmaceutical quality, and bridging local stakeholder expectations with global business priorities.   Nikhilesh Kalra arrived in Japan knowing that the country would be different, but not fully appreciating how deeply those differences would shape leadership. He had spent his career in multinational companies where junior employees were encouraged to speak up, debate was visible and success was usually framed in terms of outcomes. At SSP, he entered a 260-year-old Japanese organisation operating in healthcare, where hierarchy, quality, continuity and stakeholder alignment were woven into the operating system. His first important lesson was that formal meetings reveal only a fraction of the decision process. In an industry association meeting, agenda items passed with almost no visible debate. The real conversation had occurred beforehand through one-to-one stakeholder management. Inside SSP, he encountered meetings to prepare for meetings, and sometimes additional meetings before those. The purpose was not simply bureaucracy; the Japan team wanted to appear externally as one aligned entity. Kalra worked to reduce unnecessary internal preparation while preserving the consensus-building needed for confident execution. The largest surprise was the extent of risk aversion. Kalra came to see it not as simple timidity, but as the product of a society built around predictable service and exceptionally high quality. In pharmaceuticals, some risks must never be compromised. Yet the same perfectionist mindset can spread into areas where experimentation is essential, including digital transformation, enterprise systems and commercial processes. Organisations may retain outdated infrastructure and manual Excel-based work because changing it feels riskier than tolerating the hidden cost of inefficiency. Kalra therefore distinguishes between critical quality risk and controllable business experimentation. His challenge to employees is not merely whether they completed the process, but what they improved compared with the previous year. He asks teams to examine proposals privately, return with their collective view and explain why they support or reject them. This method respects the reluctance to disagree openly with the president while creating a genuine window for debate. Teams may reject the original idea, or propose a midpoint. Kalra often accepts the midpoint because ownership produces exceptional Japanese implementation: stakeholders are aligned, details are resolved and execution becomes disciplined. Trust was essential because employees initially saw him as someone sent from headquarters who might prioritise global demands over the Japanese business. Kalra created proof that he was on their side by fighting to retain the SSP name rather than replacing it with the multinational parent's name. The 260-year legacy mattered to employees, customers and regulators. By defending it at global level, he demonstrated respect for what generations of people had built and established that local decisions would be made according to what was right for Japan. He also relied heavily on a trusted leadership team able to disagree with him. Without strong Japanese proficiency, psychological safety among direct reports became vital. Kalra openly acknowledges that his own view may be right only part of the time. Leaders who understand customers, employees and local systems must be able to explain what he is missing. This same safety is necessary for risk-taking: when a new initiative fails, the individual who tried it should not be punished. The leader must explicitly share the risk and then walk the talk when the result is imperfect. Early commercial successes helped build the organisation's risk muscle. SSP took its first price increase in roughly 30 years after the COVID-era supply shock. Employees with prior experience showed colleagues how to proceed step by step, the company persuaded retailers and the initiative succeeded. Each successful controlled risk made the next one easier. Similarly, the supply chain team shifted from automatically satisfying every customer request to proposing alternatives that protected the customer's concern while improving SSP's economics and efficiency. Kalra believes culture cannot be replaced wholesale. It can be evolved team by team, person by person, with different functions moving at different speeds. Change agents are needed across the organisation so the entire company is not constrained by its slowest group. For expatriate leaders, his advice is to listen, be patient, create psychological safety and educate headquarters about the real consequences of rapid change. Rather than simply resisting a global request, the Japan leader should offer a data-based roadmap showing how the change can be assessed, recommended and implemented responsibly. His regret is not learning more Japanese. Language would have enabled more unscripted conversations at the gemba—with factory employees, sales representatives and frontline staff—and provided richer insight into whether strategy had reached execution. His broader leadership lesson is equally direct: people are not there to impress the president. Their job is to create value for the organisation and its real internal or external customers. The leader's role is to connect silos, protect thoughtful experimentation, maintain trust through consistent behaviour and help a traditional organisation evolve without losing the strengths that made it endure. Q&A Summary What makes leadership in Japan unique? Leadership in Japan requires understanding that visible meetings often confirm rather than create decisions. Debate commonly occurs through one-to-one stakeholder conversations, nemawashi and internal alignment before the formal session. Kalra found that disagreement with a senior leader may be silent because direct refusal can feel disrespectful. He therefore gives teams time to discuss proposals privately and return with an aligned answer. This approach respects hierarchy while creating space for authentic disagreement. Japan's emphasis on quality, continuity and collective reputation also means the leader must consider customers, regulators, employees and long-established relationships before forcing change. Why do global executives struggle? Global executives struggle when they interpret slow alignment as obstruction or assume that a direct headquarters mandate should immediately become local action. They may arrive under pressure to improve profitability and attempt dramatic changes before understanding the supply chain, customer expectations or regulatory consequences. Kalra advises leaders to educate global stakeholders with data and explain the risk of moving too quickly. Simply saying no makes the Japan organisation appear resistant. A better response is a roadmap: assess the issue, make a recommendation, identify the steps and then implement the change in a way that protects the business. Is Japan truly risk-averse? Kalra sees Japanese risk aversion as rooted in perfection, predictability and responsibility. In medicines, exceptionally high quality is non-negotiable. The problem arises when the same standard is applied to every internal process, digital tool or commercial experiment. Organisations may avoid replacing obsolete systems because change seems dangerous, even while manual work creates hidden costs. Kalra separates unacceptable product risk from manageable experimentation. He builds confidence through small proof points, experienced change agents, rigorous discussion of anticipated risks and a commitment that employees will not be penalised for well-considered initiatives that do not succeed. What leadership style actually works? The leadership style that works for Kalra combines listening, patience, local advocacy and shared accountability. He does not demand an immediate answer in the room. He asks teams to examine the issue, challenge it and return with their view. He is willing to accept a midpoint because commitment to an owned solution can matter more than theoretical perfection. Trust also requires proving that the leader serves the Japanese business rather than merely transmitting headquarters instructions. Defending the SSP name was a powerful example. Internally, he depends on psychological safety so senior colleagues can tell him when his interpretation is incomplete or wrong. How can technology help? Technology can reduce the hidden inefficiency created by old systems, manual spreadsheets and repetitive processes, but adoption requires a different risk conversation. SSP is experimenting with AI for content creation, advertising and data analytics, where speed, cost and insight can improve substantially. Kalra sees AI as a major future force and believes companies that use it well will outperform. At the same time, technology cannot be treated as a purely technical project. Leaders must clarify which risks are acceptable, involve the people affected, build confidence through pilots and ensure that modernisation improves outcomes rather than simply replacing one process with another. Does language proficiency matter? Kalra considers his limited Japanese one of his main regrets. More language ability would have enabled unscripted conversations beyond the leadership team, particularly with factory workers, sales representatives and frontline employees. Those gemba conversations help a president test whether strategy has reached execution: whether people have heard about a change, understand the reason and know what to do next. Language also reduces dependence on intermediaries and provides deeper insight into systems and employee sentiment. Such contact should be transparent, however, so direct reports understand that the leader is learning about the organisation rather than checking up on them. What's the ultimate leadership lesson? Kalra's ultimate lesson is that leadership is not about being impressed by activity or having employees perform for the boss. The organisation and its customers are the true focus. Leaders must listen, connect people across silos and judge success by improved outcomes rather than process completion alone. They must also protect trust, which can be lost very quickly through inconsistent behaviour. A leader should take collective responsibility for thoughtful risks, build change agents throughout the company and evolve culture at a realistic pace. In Japan, patience and stakeholder alignment are not alternatives to progress; they are often the conditions that make durable progress possible.   Author Credentials Dr. Greg Story, Ph.D. in Japanese Decision-Making, is President of Dale Carnegie Tokyo Training and Adjunct Professor at Griffith University. He is a two-time winner of the Dale Carnegie "One Carnegie Award" (2018, 2021) and recipient of the Griffith University Business School Outstanding Alumnus Award (2012). As a Dale Carnegie Master Trainer, Greg is certified to deliver globally across all leadership, communication, sales, and presentation programs, including Leadership Training for Results. He has written several books, including three best-sellers — Japan Business Mastery, Japan Sales Mastery, and Japan Presentations Mastery — along with Japan Leadership Mastery and How to Stop Wasting Money on Training. His works have also been translated into Japanese, including Za Eigyō (ザ営業), Purezen no Tatsujin (プレゼンの達人), Torēningu de Okane o Muda ni Suru no wa Yamemashō (トレーニングでお金を無駄にするのはやめましょう), and Gendaiban "Hito o Ugokasu" Rīdā (現代版「人を動かす」リーダー). In addition to his books, Greg publishes daily blogs on LinkedIn, Facebook, and Twitter, offering practical insights on leadership, communication, and Japanese business culture. He is also the host of six weekly podcasts, including The Leadership Japan Series, The Sales Japan Series, The Presentations Japan Series, Japan Business Mastery, and Japan's Top Business Interviews. On YouTube, he produces three weekly shows — The Cutting Edge Japan Business Show, Japan Business Mastery, and Japan's Top Business Interviews — which have become leading resources for executives seeking strategies for success in Japan.

Maria Roxana Olareanu und Robert Wagner diskutieren Highlights der American Diabetes Association Jahreskonferenz aus New Orleans, Juni 2026. MAT-DE-2604140 v1.0 09/2026, MAT-AT-2601095 v1.0 09/2026

Co-hosts Ryan Piansky, a patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Amarah, a high school senior and patient advocate living with EoE and several other chronic illnesses. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:48] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:07] Holly introduces today's topic: eosinophilic esophagitis (EoE). EoE is a chronic allergic inflammatory disease of the esophagus.   [1:19] EoE occurs when eosinophils, a type of white blood cell, accumulate in the esophagus in elevated numbers, causing inflammation that can make eating or swallowing difficult or uncomfortable.   [1:30] Holly introduces and welcomes today's guest, Amarah, a high school student who is a patient advocate living with EoE. Welcome, and thanks for joining us.   [1:37] Amarah thanks Holly and Ryan and says she is very excited to be here.   [1:50] Amarah says she is a high school senior. She loves to perform and act. She is also very involved in sports and school activities. She is a cross-country member and a soccer member.   [2:05] Amarah was diagnosed with EoE when she was very young. She has done every treatment you can think of. She has had foods that she was able to eat, and then she couldn't eat them, and then later she could go back to eating them.   [2:19] Amarah says it feels like she has had "millions and millions" of scopes. She has done transnasal scopes and regular scopes.   [2:28] Holly says she and Ryan have been on numerous types of therapy and tried diet elimination. Holly has done the transnasal scope and is excited to hear that Amarah has. Ryan says he feels left out and needs to try a transnasal scope at some point.   [2:52] Holly says we also call it a nonsedated endoscopy. Holly says she loves that Amarah has access to it. Amarah says her state is sparsely populated without those resources, so she flies down to Phoenix, where she used to live, for all of her doctoring.   [3:27] Holly says it's awesome for listeners to know that Arizona is a state where they can get treatment.    [3:47] Amarah says she had a wonderful primary care doctor when she was little. She was having problems around eight months old. At about a year-and-a-half, her primary care doctor suggested she be tested for this "new" disease, EoE. So she got tested.   [4:16] Amarah remembers "not being able to eat anything." That was her normal. She doesn't remember having to take out any foods. The first time she realized she had something more than allergies, she was around 5 or 6 years old.   [4:37] At that time, she realized that something was not the same with other kids who have allergies. What she had was different from a normal allergy.   [4:50] Amarah says she was about 10 or 11 years old when she had a better understanding of what EoE was, inside the esophagus.   [5:16] Ryan compares Amarah's experience to his own, as he was also diagnosed very young. For years, he explained it away as allergies. It's a complicated thing to grasp when you're younger.   [5:45] Amarah is on dupilumab, which is helpful for her eczema, which has resisted topical treatments. Dupilumab also helps with her EoE, so now she is able to have dairy, wheat, and soy. She can't eat them at the same level as people who do not have EoE.   [6:27] Amarah says she prefers a lot of foods that do not have dairy and wheat in them. It's helpful for traveling. She can eat dairy, wheat, and soy, and her scopes come back clean, which is nice.   [6:44] Amarah says that in the past she has done budesonide. She is on PPIs. She had Nissen fundoplication. She also did a drug trial. When she was 12, her EoE got bad. She did a drug trial for an IV drug, and it did not work. She had an adverse reaction.   [7:24] Ryan says he was taking a medication for eosinophilic asthma, which was helping his EoE a little bit, but not a lot. Now that he is taking dupilumab for EoE, that is also helping him with his eosinophilic asthma. Ryan agrees that it is such a game changer.   [7:58] Amarah says she doesn't have other trigger foods, but she is allergic to shellfish due to IgE, not EoE. Peanuts and tree nuts trigger anaphylaxis. Soy, wheat, and dairy are definitely EoE triggers. She used to have to avoid corn but is able to have it now.    [8:38] Amarah says you just know when you eat too much of a food, and your EoE is starting to act up again.    [9:15] Ryan advises listeners to double-check with your care team before you start to introduce triggers back into your diet.   [9:26] Holly says this is so relatable. Holly is significantly older than Ryan and Amarah and didn't get diagnosed until she was older. She loves how Amarah articulated the different paths she has been on as she was growing up.   [9:55] Holly notes that Amarah was at the rise of new treatments that could give her hope to try.   [10:07] Holly asks Amarah to explain to listeners the Nissen fundoplication. Amarah says she had it when she was about four, for her GERD, which is acid reflux. She says some kids with EoE have it done; some do not.   [10:50] Amarah says the sphincter between her stomach and esophagus didn't fully close. The doctor said he had never seen a sphincter look so bad.   [11:04] They did surgery to take a part of the stomach and sew it up so the sphincter closes when food goes down the esophagus, so it stays in the stomach. Amarah says you should not be able to throw up after the surgery, but she still has that ability.   [11:42] Amarah says the surgery can get looser over the years. She has had a couple of tests where the doctors monitor how loose it is.   [11:50] Holly thanks Amarah for articulating what Nissen fundoplication is. Holly is fascinated that Amarah is still able to vomit. That's an important thing to think about with EoE. Holly had the same procedure twice before they knew she had EoE.   [12:53] Amarah says EoE has a lot of layers. It's very complicated. It's very hard to describe it. It takes a lot of extra steps [to manage it].   [13:05] Amarah explains using another diagnosis she has: mild dyslexia. She has to put in more effort and work to do school assignments because she's in advanced classes that require a lot of reading, writing, and spelling.   [13:25] EoE is similar in the way that you have to have the extra steps in order to manage it. She wishes people would know that it's a multi-step process. It's not just one and done.   [13:38] Amarah has been looking at colleges. One of the things she is looking for is whether they have cafeterias she can use. Do they have a disability program she can use and get accommodations for her needs? Do they have a kitchen she can use?   [13:57] Amarah says even though she can have all these different foods, she is still anaphylactic to peanuts and tree nuts. Because EoE can randomly flare up, it's important to her that she has those options.   [14:11] Amarah says EoE is very layered, and she wishes people would understand that more. It would be more helpful for the level of acceptance and understanding, overall, of having EoE, especially as a teenager.   [14:34] Ryan says that when he started college, he sat with the university dining hall and the office of disability services to explain his EoE, EoE triggers, and anaphylactic allergies, and to ask if he could eat at the dining hall. They offered the salad bar.   [15:03] The dining hall couldn't accommodate his needs, so he was able to get a dorm with a kitchen so he could prepare his own food.   [15:18] Ryan hopes that 10 years after Ryan started college, the university Amarah chooses will be more understanding of EoE and other allergies.   [15:56] Holly says that as a speech pathologist, she sees people with all diagnoses. There are still schools that don't consider EoE a disability. It's very important to think about accommodations. A patient chose to change schools because of the lack of accommodations.   [16:36] Holly is 42. When she went to school, she didn't know she had EoE, but she had IgE-mediated food allergies, threw up often, and could only eat certain things prepared certain ways. The school said she could eat at one dining hall, but it still wasn't safe.   [17:00] Holly says it has changed in a good way, but in some places, it has not, because some people still don't understand.   [17:11] Holly talks about Amarah avoiding corn and different things. People don't realize you can have an EoE trigger to very different types of foods, not just ones that you are IgE allergic to and need an EpiPen® for. That was key information for Amarah to bring up.   [17:35] Amarah enjoys participating in her school's speech, debate, and drama team. She used EoE as the topic for her informative speech project. Holly watched a video of it, and it was amazing. Holly asks how Amarah came up with the topic.    [19:16] Amarah says that the previous year she had done an informative speech on the history of My Little Pony, of which she is a fan. She decided that for the next year she would do an informative speech on one of the six chronic illnesses she has.   [19:56] Amarah considered which of her illnesses affected her the most. She picked EoE to learn more about it for herself and to explain it better to others, more than just saying she has allergies and can't eat that.   [20:03] Amarah wanted to create something that would be digestible by everyday people for a basic understanding. She had 10 minutes for the speech, so she didn't get into the nitty-gritty of it. She really liked that she got to share it with people.   [20:24] Amarah says she met a judge whose brother had just been diagnosed with EoE. She met another kid who had EoE. He told her he never thought he would see somebody talk about EoE in an informative speech.   [20:50] Amarah says that sharing about EoE was important. She loved doing it.   [20:57] Holly says she loves that Amarah used an outlet she enjoys to share something medically significant in her life.   [21:14] Holly shares how her soccer teammates reacted when she had problems swallowing. She didn't know she had more than food allergies. She and her teammates did a drama, with her as a character always having to vomit. It was releasing to do.   [22:02] Amarah says the informative speech was extremely therapeutic for her. One of her best friends since sixth grade told her, "I had no idea that's what that was." Sharing it with people was very helpful for Amarah and, she hopes, for others.   [22:35] Ryan says it was cool that she was able to connect with others with EoE or with relatives with EoE. It is a rare disease, but people can get the diagnosis more easily these days.   [22:51] Ryan says the speech was only 10 minutes, but Amarah fit so much in those minutes, clearly and concisely. He was very impressed.   [23:22] Amarah says she used 10 sources for her research. APFED was one of her sources. She learned about the number of people who have EoE. It was interesting to learn the difference between the world rate of EoE and the U.S. rate of it.   [24:00] Amarah had not known it was equally common among everybody. Age, gender, and ethnicity do not matter. That was cool to learn.   [24:18] Amarah says it was sad to learn of the lack of public awareness. She learned that the average age of diagnosis was 35 to 50 years old because people aren't aware of it. That was saddening for her.   [25:38] Holly says it can be a missed diagnosis for a time, and it creates more inflammation in certain areas to make things worse. Holly wasn't diagnosed until she was 25. People just thought she was attention-seeking to vomit all the time.   [26:13] Holly says her primary caseload is mostly people aged 18 and up who are newly diagnosed. It's not young kids who are getting diagnosed, like when she worked at a major children's hospital.   [26:39] Holly says Amarah's speech was very informative and well-articulated. It was also dramatic, like a performance, while giving a lot of good information. Holly says it helps people retain information if they're captivated by the presenter.   [27:18] Amarah hopes her peers learned a basic understanding of EoE and some of the ways it works. She covered different treatment plans and food trials, which her peers don't understand until she explains them. That was important to her.   [27:47] Amarah says trying to figure out a way to describe a food trial to somebody who did not know took her a lot of rewrites.   [27:57] Amarah says her last paragraph was about public awareness, why you should care about EoE, and what you should know about it. It's becoming a more prevalent disease.    [28:31] Amarah says that having a basic understanding of EoE creates more acceptance. That's one of the things Amarah hopes to improve in the world.   [28:48] This year, Amarah is writing a Persuasive Essay on why disability should be more prevalent in media because of the level of diversity that it could provide.   [29:03] A lot of people, when Amarah tells them about her disability and chronic illnesses, say, "I am so sorry for you. I feel so bad for you. That must be awful. It must be absolutely horrendous for you."   [29:20] Amarah says these are sometimes the same people who say that they care, but then they do not accept her or her food allergies. They don't accommodate her. They still eat peanuts around her and refuse to wipe their hands.   [29:45] Amarah sees there is a big difference between acknowledging it and accepting it. She used the speech to show people the disability and disease of EoE, some reasons they should know about it, and why they should accept it.   [30:10] Amarah used self-deprecating humor, one of her favorite things to do. Amarah has also done quite a few stand-up comedy acts, which involve self-deprecating humor. She says it's a little bit of a way to cope.   [30:32] Amarah wanted to make something that people would engage in. If she stood up there with a monotone voice for 10 minutes, nobody would remember anything.   [30:41] Amarah says performing like that and having a space where she could show a little bit more of herself that she doesn't normally show to people was not only therapeutic to her, but she hopes that it showed people what EoE is.   [31:04] Holly says, "You just made me cry." It's a hard life lesson when you have chronic illnesses. Holly and Ryan understand that.   [31:20] Holly tells how important it is to her to see disability in the media, whether it's a patient in a medical show that has EoE, or a model in a brand-name ad that uses a cane, as Holly does for a different disability. It hits her in a way that's different.   [31:58] Holly says that seeing and hearing things in the media that are a part of dealing with her disabilities makes her feel included in a way that she never felt with some of her "closest" peers at the time.   [32:12] Ryan says it's wonderful that Amarah is doing this advocacy work through an outlet that she really enjoys and spreading that awareness outside some of these patient advocacy communities. Lack of awareness is an issue.   [32:30] Ryan says people care and want to be accommodating, but if they don't understand it and it's not being presented to them in a way they can parse through and fully understand, it's hard for them to make those steps to be accommodating.   [32:43] Ryan is glad that Amarah is continuing her advocacy work through the essay she is working on in the Speech and Debate Club.   [32:52] Ryan reflects on how great it was to have Amarah join as a patient panelist at the Annual Patient Education Conference, EOS Connection 2026, in Denver, and answer questions for a sizeable audience.   [33:08] Ryan says it was wonderful to see a high school student fielding questions. It was helpful for all the participants in the audience as well.   [33:27] Amarah says she absolutely loved it. It was wonderful. She loved hearing the other panelists' patient stories, and in general, hearing every other kid's experience with EoE. They were all different.   [33:50] Amarah enjoyed sharing her story and having a platform to relate to people. She remembers saying, "You know when your EoE is acting up because you can't eat rice. It starts to get stuck in your throat," and everybody in the audience started nodding.   [34:21] Amarah says having that relatability was helpful. She loves speaking in front of an audience, so that was great, too.   [34:33] It was a different format from the informative speech. Amarah says having to think on her feet meant she had to be more conscious of the words she was going to say. Her informative speech had a written, memorized transcript. Even her hand movements were practiced.   [35:22] Amarah says being able to talk about her biases with EoE and experiences she has had was helpful for her, and she hopes for other people, but very different from her informative speech, which is not supposed to be biased at all. It's not persuasive.   [35:48] Amarah says there were multiple times when she was writing her informative speech that she realized she could not put a sentence in it because it showed bias. She couldn't say, "you shouldn't be mean to people with EoE," for example. That's bias.   [36:21] Amarah says on the patient panel, she was able to do that. A lot of the experiences that she related on the patient panel were things she may have told her parents and some family members, but not anyone in her friend group.   [36:48] Amarah says sharing these experiences and how some of those events had made her feel or had impacted her was something she was not able to show in her informative speech. It was helpful to share her experiences on the patient panel.   [37:26] Ryan says, for our listeners, you can still access the patient panel online. We have on-demand content. We'll link to that in the show notes for this episode.   [37:36] Ryan says people can go back and watch that and hear from you and our other patient panelists. We had a great range of panelists up there. Ryan asks if Amarah learned anything that stuck with her from the panelists or presenters at this conference.   [37:52] Amarah says one of the patient panelists was talking about EoE in the workforce at her job. That was not something Amarah had thought about before. She found it really helpful and something that she will have to think about more in the future.   [38:13] Amarah met a teen who talked about his experiences of having EoE while being on sports buses and sports teams. Amarah found it helpful as she is on sports teams. The student told everyone on his team about his EoE. Amarah found that interesting.   [38:47] It gave Amarah some ideas on how to talk to people on her teams. Amarah just loved meeting all of the people at Eos Connection and learning about their different experiences and how she could improve some of her future experiences.   [39:10] Holly says a key point of the conferences is learning what's coming next in terms of treatment, diagnosis, and all the wonderful things you see health providers doing to support this diagnosis in the world.   [39:29] Holly says when you meet someone else who's going through a very similar experience, there is nothing quite like it. Holly talks about learning from the positive attitudes of other patients she meets at the conferences.   [40:12] Amarah tells EoE patients, "You don't have to tell people if you don't want to." She is a very private person when it comes to her medical stuff, especially during a flare or when there is something new happening.   [40:45] Amarah says she doesn't share it with people until she fully knows what's going on. "You don't have to share it with people if you don't want to."   [40:54] Amarah continues, "Granted, you should probably share your anaphylaxis with your teachers. 'Please don't bring peanuts in the classroom; you will kill me.' But you don't have to get into the nitty-gritty."   [41:06] Amarah continues, "You can just say, 'I have a medical disease. It affects me on a daily basis. I don't want to talk about it.' That is completely OK."   [41:17] Amarah continues, "You do not have to explain anything to somebody. You are not required to. You don't have to. It is your own body. It is your own choice when telling people things."   [41:31] Amarah continues, "It sucks sometimes, and especially kids with EoE, they may have a lot of other chronic illnesses, like me, where everything is combined at once."   [41:48] Amarah continues, "Once something flares up, then the other thing flares up. It sucks sometimes. And that is OK. It is OK that it sucks sometimes. You just have to get through it. You can't wallow in it, but you can acknowledge it."   [42:07] Amarah continues, "If you sit there and 'everything is fine, everything is great,' well, you know, you're actively having a reaction; it's clearly not. And that is something that I still work on today: pretending that everything is fine when it's not."   [42:26] Amarah continues, "You're not going to be perfect. I'm still not perfect. I struggle with talking to people, sharing my experiences, pretending that everything is fine even though I need help, or using self-deprecating humor when it's a serious problem."   [42:52] Amarah continues, "You're not perfect. That's OK.   [42:58] Ryan says that's such a good thing to keep in mind for the patients out there, that it's a journey. There are ups and downs. Finding your comfort level and maturing about the disorder, and keeping in mind that it's not going to be a perfect day every day.   [43:16] Ryan says, Amarah, I'm really glad you were able to join us on this podcast. It was so good to see you at the conference over the summer, as well.   [43:21] I think you're such a wonderful patient advocate. I'm so inspired to see you engaging so much with the community both at APFED and more broadly, speaking about your eosinophilic disorder through these other outlets that are meaningful to you.   [43:39] I know all our listeners are going to appreciate that as well.   [43:44] For our listeners who do want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes.   [43:50] If you're looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder, available at apfed.org/specialist.   [44:00] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experiences, please check out apfed.org/shareyourstory.   [44:09] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.    [44:20] Ryan thanks Amarah for joining us. This was such a wonderful conversation, and I'm really glad that we were able to have this discussion today.   [44:27] Amarah thanks Ryan and Holly. "I do appreciate it. This was wonderful."   [44:32] Holly thanks APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda for supporting this episode. Holly thanks Amarah.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.orgapfed.org/specialist apfed.org/connections Eos Connection 2026 Education Partners: This episode of APFED's podcast is brought to you thanks to the support of AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   Tweetables (Edited):   "I love to perform and act. I am also very involved in sports and school activities. I am a cross-country member and a soccer member. I was diagnosed with EoE when I was very young." — Amarah   "It feels like I have had 'millions and millions' of scopes. I have done transnasal scopes and regular scopes." — Amarah   "I remember not being able to eat anything. That was my normal. I don't remember having to take out any foods. The first time I realized I had something more than allergies, I was around 5 or 6 years old." — Amarah   "EoE is very layered, and I wish people would understand that more. It would be more helpful for the level of acceptance and understanding, overall, of having EoE, especially as a teenager." — Amarah   "Having a basic understanding of EoE creates more acceptance. That's one of the things I hope to improve in the world." — Amarah   Guest Bio: Amarah is a high school senior living in Montana. She has EoE and several other chronic illnesses. She loves public speaking and acting. A fun fact about Amarah is that she owns 14 wigs (she loves to create costumes).

What if clinical trials could evaluate multiple treatment approaches at the same time and adapt as evidence emerges? In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Jeremy Chataway of University College London and Prof. Daniel Ontaneda of Cleveland Clinic about multi-arm, multi-stage clinical trials and their potential to make MS research more efficient and responsive. The episode comes at an especially timely moment. This week, interim results from the OCTOPUS trial showed that alpha-lipoic acid will progress to the next stage of the trial, while the metformin arm will be stopped. These results provide an early demonstration of the adaptive approach discussed in this episode — although the conversation itself was recorded before the interim results were available. Together, they discuss: How multi-arm, multi-stage trials differ from traditional clinical trial designs Why these approaches could be particularly valuable in progressive multiple sclerosis How a single trial framework can allow promising treatments to advance while less promising approaches are stopped The potential benefits for recruitment, participant experience and reducing the time between trial phases The statistical and practical challenges involved in designing and running these complex studies How interim outcomes, imaging and biomarkers could help identify promising treatments earlier What the OCTOPUS trial is investigating — and how its design is being used to evaluate potential treatments for progressive MS Whether the same approach could be used to accelerate the development of remyelination and repair therapies As the first OCTOPUS interim results now show, the adaptive design discussed in this episode is not simply theoretical. This episode offers a particularly relevant look at the thinking behind the trial and the methodology being used to determine which treatments should move forward and which should not. This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

This episode covers:  The role of AI in heart failure and prevention AI advances in interventional cardiology Training cardiologists of the future Host: Fielder Camm Guests: Benjamin Meder, Pim van der Harst, Jozine ter Maaten and Mark Westwood Want to watch that episode? Go to: https://esc365.escardio.org/event/2554 Disclaimer: ESC TV Today is supported by Novartis and Novo Nordisk through independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Dan Atar, Yasmina Bououdina, Fielder Camm, Nicolle Kraenkel, Jozine Ter Maaten, Pim Van der Harst and Mark Westwood have declared to have no potential conflicts of interest to report. Carlos Aguiar has adeclared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Benjamin Meder has declared to have potential conflicts of interest to report: Alexion, Alynlam, Amgen, Apple Inc., AstraZeneca, Bayer AG, BNK, Biontech, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Daiichi Sankyo, Deutsche Gesellschaft für Kardiologie, German Center for Cardiovascular Research, German Research Foundation, Hummingbird Diagnostics, Intellia, Johnson&Johnson, Klaus-Tschira Foundation, Informatics for Life, Leducq Foundation (CASTT), Novartis, Novo Nordisk, Pfizer, SA, Sixt, SMT, Space X, Zoll. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

India supplies a fifth of the world's medicines and invents almost none of them. Venkat Nelabhotla spent three decades inside that industry before co-founding Vyome, and here he explains where drug discovery in India stalls, and why he took a rare disease drug to the Nasdaq instead. Few operators have run a shampoo brand, a vaccine company and a Nasdaq listed biotech. Venkat Nelabhotla took CavinKare from 21 crores to 200 crores, launched India's first recombinant hepatitis B vaccine at Shantha Biotechnics at 300 rupees against the multinationals' 800, and ran Emami as CEO while its market cap went from 200 million dollars to 1.5 billion. Then he co-founded Vyome with a Harvard professor and went after malignant fungating wounds, the open lesions advanced cancer leaves on the skin, for which no FDA approved drug exists anywhere. Speaking with host Akshay Datt, he lays out the rare disease drug development strategy behind a phase two trial that ran on just 15 patients, and his own index of drug discovery in India: if America is 100, China is 40 and India is two or three. It arrives as US tariffs push the Indian pharma industry to think past generics.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development. Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights GSK's strategic focus on expanding its oncology pipeline through cutting-edge immunotherapeutic approaches. Trispecific T cell engagers are an emerging class of biologics that bind to three different targets simultaneously, effectively arming the immune system to recognize and destroy cancer cells more efficiently. This acquisition not only strengthens GSK's position in the competitive oncology market but also addresses a significant need for more effective multiple myeloma treatments. In parallel, Curium has achieved a notable milestone with the FDA approval of Bexlutry, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This therapy utilizes radioactive isotopes attached to molecules that specifically target cancer cells, delivering radiation directly while minimizing harm to healthy tissue. The approval of Bexlutry is a crucial development in oncologic care, expanding treatment options for patients dealing with complex and heterogeneous tumors. It underscores the growing role of targeted radiotherapies in providing precision medicine solutions. On the financial front, Electra Therapeutics is gearing up for an initial public offering (IPO) to raise $325 million. The proceeds are intended to advance its late-stage clinical trials for severe hemophagocytic lymphohistiocytosis (SHLH), a rare autoimmune condition. This move reflects a broader trend among biotech companies turning to public markets to support niche therapeutic areas with high unmet needs and potential orphan drug status benefits. Turning to clinical advancements, Corbus Pharmaceuticals has reported encouraging Phase 1b data for CRB-913, which employs CB1 inverse agonism in combating obesity. By modulating endocannabinoid activity linked to appetite and energy balance, this approach offers a promising direction for managing metabolic disorders. Simultaneously, CSL Seqirus has shared Phase 3 results showcasing the superior efficacy of its MF59-adjuvanted cell-based quadrivalent influenza vaccine in older adults, highlighting ongoing innovations in vaccine technologies tailored for vulnerable populations. The FDA's regulatory landscape is also evolving with the launch of Operation Trialblazer. This initiative seeks to streamline early-phase U.S. clinical trials through expedited IND application processes, facilitating faster transitions from research to clinical applications and fostering innovation by reducing bureaucratic hurdles. Meanwhile, the FDA is preparing for potential psychedelic medicine approvals, ensuring robust oversight frameworks are in place as these therapies near market availability. Yet, as always in drug development, challenges persist. Novo Nordisk's decision to terminate its GLP-1 obesity drug partnership with Ascendis following unsatisfactory results exemplifies the inherent risks even promising preclinical data can present. Similarly, setbacks faced by Axoltis Pharma and Eli Lilly with their neurological and metabolic candidates reinforce the complexities of translating scientific hypotheses into viable therapies. Sanofi has taken significant strategic steps as well by divesting 20 older medicines and three manufacturing sites to Cheplapharm. This decision aligns with Sanofi's focus on innovation under CEO Paul Hudson's leadership and allows the company to reallocate resources towards groundbreaking therapies. In diagnostic advances, the FDA's approval of Telix's Pixclara marks a breakthrough for brain cancer imaging. Being the first FET-PET imaging drug approved for gliomas, Pixclara could significantly enhance diagnostic accuracy and treatment planning for these challenging tumors. These developments underscore a transformative period where scientific innovation is paired with strategic regulatory adjustments to navigate complex market dynamics. As companies continue adapting to these changes, their ability to innovate while addressing safety and efficacy concerns will be critical in advancing therapeutic frontiers and improving patient outcomes across diverse medical landscapes. As always, we'll be here at Pharma Daily to keep you informed on these pivotal changes shaping our industry's future. Thank you for tuning into today's episode of Pharma Daily. Keep innovating and stay informed!Support the show

Je rencontre ce jour Denis Ferrand, Directeur Général de Rexecode.Rexecode fait partie de ces organisations discrètes et pourtant centrales en France. Beaucoup d'associations professionnelles en sont membres. Quelques-unes de nos plus grandes sociétés aussi comme Sanofi, St Gobain ou encore TotalEnergies.Prenez un sujet économique et demandez-vous comment obtenir une analyse dénuée de toute idéologie. Rexecode ne sera jamais loin.Quand je me demande comment va la France – et nous sommes un peu plus nombreux chaque jour – je me dirige vers Rexecode.Du reste, c'est un peu le sujet du jour. Comment va la France ? Et que faire ?Deux heures n'ont pas suffi à Denis et moi pour faire le tour de la question mais nous abordons des thèmes qui devraient vous parler : la dette publique, le budget de la nation, la désindustrialisation, la tech et l'IA et enfin les talents d'aujourd'hui et de demain.Promis, pas de langue de bois. Juste les faits, une vision des grandes tendances auxquels nous n'échapperons pas et quelques pistes pour redresser notre beau pays.Bonne écoute.Si cette nouvelle interview vous a plu, parlez-en autour de vous, notez 5 ⭐ le podcast (Spotify, Deezer, ApplePodcast...) et rédigez un avis.N'hésitez pas à m'écrire sur LinkedIn, à vous abonner à notre Newsletter hebdo et à notre nouvelle chaîne YoutubeToutes les Histoires d'Entreprises sont également disponibles sur histoiresentreprises.com et sur le site de bluebirds.partners, site de la communauté d'indépendants que j'anime et qui conseille ou remplace des dirigeants. Un podcast co-réalisé avec Agnès GuillardHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Der Wochenstart bleibt schwierig: Der DAX verliert 0,5 % auf 25.441 Punkte, der EuroStoxx50 1,1 % auf 6.254 Punkte. Brent steigt zeitweise auf rund 109 USD, europäisches Erdgas bis auf 84,20 Euro je Megawattstunde. Neue Angriffe auf Saudi-Arabien und Schiffe im Golf verschärfen die Sorgen um die Energieversorgung. Gleichzeitig erreicht die Rendite zehnjähriger US-Staatsanleihen die Marke von 5 %. Vor der Fed-Sitzung steigt damit der Zinsdruck. Zusätzlich geraten KI-Aktien weltweit unter Druck. Hochtief fällt 9,8 %, Infineon 7,7 %, Aixtron 11,2 %. Deutsche Börse gewinnt 2,1 % wegen Spekulationen über Euronext. Novo Nordisk tritt künftig als Novo auf, Sanofi beteiligt sich mit 26,4 % an Cheplapharm. Bayer wartet nach der Roundup-Anhörung weiter auf die Entscheidung. Börsenweisheit von Gerald Loeb: "Der wichtigste einzelne Faktor für die Börse ist die Psychologie der Anleger."

The blood–brain barrier is a highly specialised interface that regulates the movement of cells, molecules and nutrients between the circulation and the central nervous system. But what happens when this critical barrier becomes dysfunctional in multiple sclerosis? In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Elga de Vries of Amsterdam UMC and MS Center Amsterdam about the evolving science of blood–brain barrier dysfunction in MS. They explore how the blood–brain barrier functions in health, how its disruption relates to immune cell infiltration and inflammatory disease activity, and why research increasingly suggests these changes may remain relevant across different stages of MS. The conversation also looks at innovative blood–brain barrier-on-a-chip models, how existing MS treatments interact with the barrier, and emerging approaches designed to transport therapies more effectively into the CNS. Finally, they consider an intriguing future direction: could strengthening the blood–brain barrier itself become part of the therapeutic strategy for MS? This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Roche, Sanofi, and UCB.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UAA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 30, 2027.Optimizing Care to Improve Quality of Life in Moderate to Severe Asthma: Strengthening Systems, Uniting Teams In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

A few years ago, when we talked about screening for type 1 diabetes, it still felt a little bit like we were talking about the future. That future may be arriving faster than we realize. Dr. Bryce Nelson is back on the show. After years as a pediatric endocrinologist, he's now working specifically in autoimmune type 1 diabetes with Sanofi. We talk about how much has changed with screening, what we're learning about who's at risk, and the big question: how close are we to screening becoming a routine part of healthcare? And Jenny Hoffman shares what this looks like for a family living it. Her older son was diagnosed at two and a half; after years of screening her younger son, Asher, he tested positive for five autoantibodies at age six. He's still in stage one, and Jenny talks about the surprising difference between fearing a diagnosis and having the time to prepare for one. Where is type 1 screening headed next? That's what we're talking about today. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about screening: https://www.screenfortype1.com/ Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of Marrow Masters, we talk with Lori Eberly, a licensed social worker at OHSU Knight Cancer Institute, about the emotional and social realities of living with chronic Graft-Versus-Host Disease. Finishing cancer treatment does not always bring the relief survivors expect. Many people feel grateful that the cancer is gone while also fearing relapse and managing continuing symptoms, pain, appointments, and medication. It can feel as though one diagnosis has been exchanged for another. We address the psychological distress that can accompany chronic GVHD. Depression, anxiety, loneliness, and social withdrawal can be overlooked when appointments focus mainly on physical symptoms. Survivors should treat changes in mood and relationships as legitimate medical concerns. Providers can help by asking simple questions about coping and connecting patients with social workers, counselors, psychiatrists, and other members of the care team. Chronic GVHD can also affect identity. Survivors may question who they are after transplant and what parts of their former lives remain. Journaling, counseling, and honest conversations can help us identify what has not changed at our core. We also need space to acknowledge losses that others may not recognize. A friend or caregiver does not always need to solve the problem. Listening without interrupting or immediately offering advice can help a survivor feel heard and less alone. Financial pressure is another important concern. Reduced work hours, disability, retirement, frequent appointments, transportation expenses, and medical costs can create significant stress. Oncology social workers may be able to identify grants or other forms of assistance. Relationships can change as well. A spouse, parent, sibling, or friend may move into a caregiver role, creating a different balance of responsibilities. Honest communication can help patients and caregivers find new ways to contribute and remain interdependent. We also talk about defining quality of life personally. Joy may come from family, pets, gardening, music, nature, spirituality, or quiet time alone. These connections can help regulate the nervous system and restore a sense of safety. Gratitude and mindfulness may be useful, but they should not become toxic positivity. Survivors need permission to admit when they feel exhausted, lonely, angry, or discouraged. Coping strategies should be personal and manageable. We can begin by writing down what helps on ordinary days and what helps on the hardest days. Instead of attempting several major changes at once, we can choose one small action and see how it works. A meaningful activity may also be adapted. Someone who no longer has the energy to bake or preserve food alone might do it with a partner and gain both practical help and connection. Caregivers need support and respite too. Ignoring their own needs can lead to exhaustion and resentment. Patients and caregivers can strengthen their relationships by naming what they miss, acknowledging shared losses, and finding modified ways to enjoy life together. Across the episode, the central message is that survivors are more likely to thrive when they advocate for themselves, use the full multidisciplinary care team, maintain meaningful connections, and continue making room for joy. Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ (00:00) Intro (01:16) Cancer-free after transplant: Now what? (02:57) Depression, anxiety, and psychological distress (04:32) Making emotional health part of medical care (05:15) How chronic GVHD affects identity (07:40) Acknowledging grief and bearing witness (08:56) Work, finances, and changing relationships (12:36) Gratitude without toxic positivity (14:23) Defining quality of life personally (15:33) Connecting with self, others, nature, and spirit (18:52) “Name it to tame it” and acknowledging loss (20:31) Coping strategies and peer-support resources (21:49) Assessing what helps on difficult days (24:30) Adapting meaningful activities (25:42) Nervous-system regulation strategies (29:17) Using the multidisciplinary GVHD care team (31:22) Isolation and the loneliness of rare disease (34:38) Supporting long-term caregivers (36:42) Naming losses within relationships (39:33) Survivor stories of purpose and connection (42:38) Closing thoughts (42:59) Outro and podcast resources National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we hear from Joanne Claxton, wife and caregiver to acute myeloid leukemia (AML) survivor Adam Claxton. Adam was a guest in Season 20 and you can listen to his episode here. Joanne takes us back to Adam's diagnosis in 2024. He had a persistent cough and had visited his general practitioner several times. After being sent home with antibiotics, he went to the hospital's accident and emergency department. He was initially discharged but was soon called back and told to pack a bag. After an anxious wait, two hematology consultants told Joanne and Adam that he had AML. The news shocked their entire family. While Adam underwent chemotherapy, Joanne had to protect a sense of normality for their three children. She stopped working and took on the responsibilities of solo parenting while Adam remained in the hospital. When Adam relapsed in 2025, Joanne found the experience even more difficult than the original diagnosis. He had completed chemotherapy and a transplant and appeared to be recovering well. He had even been exercising the day before the relapse was discovered. Because he was home rather than hospitalized, the family lived with greater uncertainty. Joanne says this was the point when she hit rock bottom. After transplant, Adam developed chronic Graft-Versus-Host Disease, or GVHD, affecting his skin. But Joanne and Adam view it as the price of continued protection against leukemia. This perspective does not remove the difficulty, but it helps them face the condition with hope. Their cancer experience also brought them closer. They had not planned to marry before Adam became ill, but his diagnosis changed their priorities. They married during the journey and developed a deeper understanding of one another. Joanne is honest about the delayed effects of caregiving. She experienced anxiety, vertigo, headaches, neck pain, and other physical signs of stress. She eventually reached out for help and learned that caring for herself was necessary. She no longer allows guilt to prevent her from taking time for herself. Peg asks Joanne what the hardest moment was - and her answer is striking. Joanne's main advice to caregivers is to surround themselves with supportive people, talk openly, accept help, and use available charities and caregiver networks. No matter how strong someone may be, caregiving should not be carried alone. Joanne also reminds friends and family to ask how the caregiver is doing. Ordinary conversations can provide relief when illness has consumed every part of life. Above all, Joanne and Adam live one day at a time and choose faith over fear. Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ (00:00) Intro (01:14) Adam's acute myeloid leukemia diagnosis (03:24) Watching a partner go through treatment (05:18) Why the relapse felt even harder (08:13) Understanding graft versus host disease (09:50) How cancer changed their relationship (12:56) Advice for partners and caregivers (15:39) The helplessness caregivers experience (17:34) Releasing caregiver guilt (18:00) Difficult conversations about wills and funerals (20:08) Faith over fear after a GVHD diagnosis (23:09) The importance of ordinary conversations National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We speak with Dr. Ryan Lee of Memorial Sloan-Kettering Cancer Center about dental care before, during, and after a bone marrow or stem cell transplant. Dr. Lee is a chief dental officer, lieutenant colonel, oral oncologist, and implantologist. He explains why dental planning must consider more than the immediate transplant period. As treatments improve, many survivors are living for decades. Their teeth and gums need to support them throughout long term survivorship. Patients undergoing transplant may face weakened immunity, infection, bleeding, mouth sores, dry mouth, pain, taste changes, and difficulty chewing or swallowing. These problems can occur together and make each other worse. A mild dental issue can become a serious infection when blood counts are low. Poor oral health can also interfere with eating and maintaining proper nutrition. Dental clearance should identify teeth that must be treated before transplant and problems that can safely wait. Dr. Lee stresses that this decision is different for every patient. Dentists need to understand the type of transplant, the likelihood of Graft Versus Host Disease, current medications, and the expected long term condition of each tooth. Communication between the dental team and the hematology and oncology team is essential. A strong daily oral care routine should begin before treatment. Patients should use a medium or soft toothbrush, clean between the teeth, and consider a water flosser when regular flossing causes bleeding. Dentures, partials, crowns, bridges, and implants require careful cleaning because they can collect bacteria and fungus. Patients should also know where these restorations are located so future dental providers can give specific instructions. Saliva acidity and dry mouth should also be discussed because they can greatly increase cavity risk. During treatment, mucositis may cause painful sores throughout the mouth. Frequent water intake, nutritional drinks, and prescribed mouth rinses may make eating more manageable. Some rinses contain antimicrobial medication and lidocaine to reduce infection risk and temporarily numb the mouth. Dental procedures must be planned around blood counts and medication schedules. Invasive work may be safest shortly before the next chemotherapy or immunosuppressive treatment, when blood counts have had the most time to recover. During neutropenia, elective treatment may need to stop while the dentist focuses on controlling pain and infection. During thrombocytopenia, extractions or other procedures may need to wait because bleeding may be difficult to control. Dr. Lee recommends creating a dental timeline that separates urgent pretransplant treatment from work that can wait six, twelve, eighteen, or twenty four months. Long term survivors should build a consistent relationship with dentists and hygienists who understand their medical history. Pediatric survivors require additional support because treatment can affect developing adult teeth, tooth roots, spacing, appearance, and self confidence. The central message is that dental care is part of transplant care. Early planning, daily prevention, current blood count information, and communication between providers can protect comfort, nutrition, and quality of life for many years. Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ (00:00) Introduction (01:12) Why dental care matters before transplant (02:23) Common oral complications (04:12) Which dental problems need treatment first (05:38) Transplant type and graft versus host disease risk (06:45) Protecting teeth for long term survivorship (10:39) Cleaning dentures, crowns, bridges, and implants (11:51) Saliva acidity and cavity risk (12:47) Mouth sores, bleeding, and trouble eating (13:57) Managing pain and maintaining nutrition (15:28) Dental care with low blood counts (17:29) Managing dentistry during neutropenia and thrombocytopenia (23:00) Long term dental survivorship (24:48) The role of dentists and hygienists (25:46) Oral graft versus host disease and limited mouth opening (27:34) Dental health decades after transplant (28:03) Dental development in pediatric survivors National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today hear from Julia Oppman, a two time acute myeloid leukemia survivor (AML)and patient advocate from Northeast Ohio. Julia shares how her cancer journey began in 2018 when she was 36 years-old and raising two young children. She initially blamed her extreme exhaustion on motherhood and work. After months of illness and repeated infections, she was diagnosed with AML. The diagnosis came unexpectedly by phone and was followed almost immediately by a 30 day hospital stay for induction chemotherapy. Julia later underwent minimal residual disease (MRD) testing. Eventually, the numbers increased and she relapsed in 2020. She was told that a bone marrow transplant was now necessary to save her life. The transplant took place during the COVID pandemic, creating additional challenges for Julia and her family. Hospital visitor restrictions led them to relocate so she could receive treatment at a hospital that allowed support people. Her husband, mother, and children became an essential part of her care during the transplant and the critical first 100 days afterward. Following transplant, Julia developed chronic Graft Versus Host Disease. She describes it as one of the most challenging parts of her experience because it can affect multiple areas of the body at different times. Her symptoms have required visits with many specialists, and she has struggled to find treatments that work for her. Insurance denials have created another barrier, especially when doctors want to consider medications that are not specifically labeled for Graft Versus Host Disease. Julia has become a strong advocate for herself and others. She sought evaluation at the National Institutes of Health (NIH) and plans to pursue additional expertise at Memorial Sloan Kettering Cancer Center in New York. She encourages patients to look for support groups, connect with others who have similar experiences, and continue searching for medical resources when existing options are not enough. One of Julia's biggest sources of purpose is her 'Share the Love' initiative. What began as Valentine's Day gifts for patients on her hospital floor has grown into an annual effort serving several hospitals, including a children's hospital. Her children now help create handmade Valentines for the packages. Julia also shares the unexpected birth of her youngest child after being told she would not be able to have more children. Through cancer, transplant, chronic GVHD, advocacy, motherhood, and giving back, she continues looking for what she calls the silver lining. Her message is clear. Life after transplant is not always simple or easy. Support often means showing up, listening, helping with every day tasks, and allowing patients to be honest about what they are experiencing. If you want to help Julia's Share The Love initiative, you can reach her at: jewelsjean@hotmail.com Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ Additional Resources: National Institutes of Health (NIH): https://www.nih.gov/ GVHD Alliance: https://www.gvhdalliance.org/ NeedyMeds: https://www.needymeds.org (00:00) Introduction (01:03) How Julia's cancer journey began (06:04) Relapsing during the COVID pandemic (07:18) Facing a bone marrow transplant in 2020 (08:09) Relocating the family and finding caregiver support (11:03) Creating the Share the Love Valentine's initiative (13:31) Living with chronic graft versus host disease (15:51) Resources for medication assistance (16:08) Seeking answers at NIH and Memorial Sloan Kettering (19:58) Support groups and learning from other patients (21:14) An unexpected pregnancy after transplant (23:31) Insurance barriers and financial toxicity (24:37) Putting the broken pieces of life back together (27:05) How friends can truly support patients National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We talk with Dr. Yazan Migdady about chronic Graft Versus Host Disease, post transplant cytopenias, and what patients and caregivers should understand about recovery after a blood or marrow transplant. Chronic GVHD develops when the donated immune system begins reacting against the patient's own cells. Dr. Migdady explains that it occurs in roughly half of transplant patients, although severe cases are much less common. When GVHD affects the bone marrow, it can interfere with the body's ability to produce healthy red blood cells, white blood cells, and platelets. Low blood counts after transplant can have several causes. GVHD itself may interfere with blood production or cause the immune system to attack blood cells. Medications used to control GVHD can also lower blood counts. Infections, poor graft function, and other transplant related complications can contribute as well. This is why regular monitoring and a thorough evaluation are so important. Dr. Migdady also explains when transfusions may be needed. Decisions are based not only on laboratory numbers but also on symptoms, bleeding risk, medications, and the patient's overall condition. Transfusions provide temporary support while the body is unable to produce enough blood cells on its own. Treatment options continue to improve. In recent years, several therapies for chronic GVHD have become available, giving clinicians more ways to individualize care. Clinical trials remain an important part of that progress and can sometimes give patients access to promising treatments years before they become widely available. Researchers are also investigating more targeted approaches for immune mediated cytopenias. The goal is to target the specific immune cells or pathways responsible rather than broadly suppressing the immune system. We also address the common idea that chronic GVHD eventually "burns out." For many patients, symptoms do improve as the immune system gradually settles down, and some can eventually stop treatment. However, this process varies considerably. GVHD can last months or years and can flare again, so patients need continued monitoring. Finally, we focus on the emotional side of recovery. Isolation is intended to protect patients while their immune systems are vulnerable, but staying connected with family and friends remains important. Caregivers should prepare for a marathon rather than a sprint, build their own support network, and take care of their own physical and emotional needs. Dr. Migdady closes by sharing several memorable patient stories that remind us that advances in transplantation are ultimately about the people behind the science. Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ (00:00) Intro (01:52) What Is Chronic Graft Versus Host Disease? (03:53) Can a Little GvHD Be Beneficial? (05:25) Why Blood Counts Can Stay Low After Transplant (07:50) Finding the Right GvHD Treatment (08:43) Why Clinical Trials Matter (09:58) When Are Blood Transfusions Needed? (11:58) New Therapies for Post Transplant Cytopenias (14:20) Does Chronic GvHD Eventually Burn Out? (15:56) Coping With Isolation During GvHD (17:36) Advice for Caregivers (19:43) Patient Stories That Made a Lasting Impact (22:36) Closing Thoughts National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We meet Mitch McPherson, a Georgia law enforcement officer who was diagnosed with high risk myelofibrosis in February 2025. His symptoms began months earlier with fatigue, weakness, shortness of breath, and facial tingling. Mitch learned that a stem cell transplant offered his best path forward, but his doctors worried that finding a young, fully matched donor could be difficult. Within days, Mitch received unexpected news. Multiple donors were perfect 10 out of 10 matches. The first donor could not meet the required schedule, but a second donor, a 26 year-old woman from the United States, agreed to proceed. Mitch also received support from DKMS and members of his sheriff's department, who organized a donor registration drive. Before the transplant, Mitch took Vonjo to reduce the risk of his disease progressing to leukemia. He then completed five days of intensive chemotherapy and received his stem cell transplant on June 11, 2025. Due to his fitness. he tolerated intense chemotherapy better than he expected, but the effects became more difficult during the following weeks. At one point, he took about 27 pills twice a day. Mitch later developed Graft Versus Host Disease, or GvHD. It caused mouth pain, dry eyes, itching, fatigue, weakness, altered taste, and difficulty eating. Foods with vinegar burned his mouth, while soft foods, dairy, fruit, baked potatoes, and bean burritos were easier to tolerate. The illness also reduced his strength so severely that he had to begin rebuilding muscle with five pound dumbbells. His recovery became harder because he returned to work far earlier than his doctors recommended. He later developed pneumonia and a blood clot in his lung. His doctors then removed him from work for six months. Mitch says the experience changed his outlook and revealed which relationships were dependable. Faith remained central throughout his journey. Interestingly, a year before his diagnosis, Mitch dreamed that Jesus told him he would become sick, but would be okay. That message gave him confidence during his diagnosis, donor search, transplant, and complications. Mitch's strongest advice is simple. We should not try to prove our toughness by ignoring medical guidance. When doctors tell us to rest and allow the body to heal, we need to listen. Mitch now focuses on recovery while finding new outlets through fishing, a possible YouTube channel, and songwriting. Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ (00:00) Intro (01:33) Symptoms and Myelofibrosis Diagnosis (03:51) Multiple Perfect Donor Matches (05:46) Medication, Chemotherapy, and Transplant Preparation (08:43) Living With GvHD (11:27) Support, Isolation, and Changing Relationships (13:44) The Dream That Gave Mitch Hope (16:52) Returning to Law Enforcement After Transplant (20:22) Recovery, Mental Health, and Ongoing Treatment (23:17) Mitch's Advice for Transplant Patients National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JYY865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until August 23, 2027.Collaborative Approaches to Biologic Therapy in CRSwNP: Connected Systems, Better Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TUX865. CME/MOC/AAPA/IPCE credit will be available until August 25, 2027.Closing the Diagnostic Gap in Eosinophilic Esophagitis: Turning Emergency Visits Into Earlier Recognition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JYY865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until August 23, 2027.Collaborative Approaches to Biologic Therapy in CRSwNP: Connected Systems, Better Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this episode, Yan Kugel and Konrad Sägesser discuss the latest trends and practical solutions in pharmaceutical water quality monitoring. Learn how continuous analytics, compliance, sustainability, and AI are reshaping water management in pharma manufacturing.Konrad is a Key Account Manager at Swan Analytical Instruments. He is a subject matter expert and co-author of the A3P Guidelines, alongside industry experts from Sanofi, BWT, and Veolia.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TUX865. CME/MOC/AAPA/IPCE credit will be available until August 25, 2027.Closing the Diagnostic Gap in Eosinophilic Esophagitis: Turning Emergency Visits Into Earlier Recognition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Season 21 of Marrow Masters, out September 3rd, focuses on Chronic Graft vs. Host Disease, You'll hear from survivors, clinicians, and more. They will share their experiences, advice, coping mechanisms, updates and tips, so you can enjoy life to the fullest, even while battling GvHD. Thank you to our Season 21 sponsors: Incyte: http://www.incyte.com/ Sanofi: http://www.sanofi.com National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TUX865. CME/MOC/AAPA/IPCE credit will be available until August 25, 2027.Closing the Diagnostic Gap in Eosinophilic Esophagitis: Turning Emergency Visits Into Earlier Recognition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JYY865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until August 23, 2027.Collaborative Approaches to Biologic Therapy in CRSwNP: Connected Systems, Better Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

What can decades of successful vaccine advocacy teach every patient organization?  Effective advocacy goes beyond raising awareness. It builds trust, removes barriers, collaborates with many partners, and empowers patients to make informed decisions. In this episode, host Eric Racine and co-host Courtney Fahey of Sanofi are joined by Amy Pisani, CEO of Vaccinate Your Family. Drawing from more than 30 years of leadership in vaccine advocacy, Amy shares lessons on how to combine scientific evidence with personal stories, work with trusted messengers, equip community partners with practical resources, and continually adapt as the information and public health landscapes change.In this episode, you'll learn about:What it takes for advocacy to go beyond awareness to remove barriers and improve patient access to care and prevention How to build trust through credible messengers, respectful communication, and collaborationEffective ways to combine personal stories and science to educate and inspire actionHow coalition building and strategic partnerships can strengthen advocacy efforts and impactPractical communication approaches, including the CASE method, to address concerns, build confidence, and support informed decisionsHow strong leaders evolve their organizations, adapt to changing needs and environments, and remain grounded in their mission over timeThis episode distills the foundations of effective advocacy into practical lessons every advocacy leader can put into action: building trust, mobilizing partners, removing barriers, advancing health policy, and improving health of the people you serve.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JYY865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until August 23, 2027.Collaborative Approaches to Biologic Therapy in CRSwNP: Connected Systems, Better Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TUX865. CME/MOC/AAPA/IPCE credit will be available until August 25, 2027.Closing the Diagnostic Gap in Eosinophilic Esophagitis: Turning Emergency Visits Into Earlier Recognition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JYY865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until August 23, 2027.Collaborative Approaches to Biologic Therapy in CRSwNP: Connected Systems, Better Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TUX865. CME/MOC/AAPA/IPCE credit will be available until August 25, 2027.Closing the Diagnostic Gap in Eosinophilic Esophagitis: Turning Emergency Visits Into Earlier Recognition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show

On this episode of the IPhO Podcast, we're featuring the winner of our 2025-2026 VIP Case Competition, the University of California, San Francisco (UCSF)! We're joined by Kat Gallison, third-year PharmD student; Maggie Khoury, third-year PharmD student; and Demi Anastasiadis, Lead, US Public Affairs & Patient Advocacy at Sanofi. Kat, Maggie, and Demi discuss the role of patient advocacy in the pharmaceutical industry, including how collaboration with patients and key stakeholders can help address barriers to care and improve patient outcomes. Kat and Maggie also share their experiences in the VIP Case Competition, how it expanded their understanding of the pharmaceutical industry, and their perspectives on patient advocacy as a new functional area in the competition. This episode pulls back the curtain on the VIP Case Competition, sharing insider information about Sanofi's sponsorship, the UCSF team's in-person presentation and visit to Sanofi's offices, and their approach to identifying and addressing unmet patient needs. Listen now!

Co-hosts Ryan Piansky, a patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Timothy Buckey, MD, MBE, an allergy and immunology attending physician with a joint faculty position at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [00:48] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   [1:04] Ryan introduces co-host Holly Knotowicz. Ryan just returned from APFED's 24th Annual EOS Connection Patient Education Conference. It was a wonderful time. Listeners can still check out the resources on demand online.   [1:26] Ryan mentions that a handful of people came up to him at the conference to say how much they appreciate the Real Talk podcast. It was wonderful to hear how impactful the podcast has been for them.   [1:53] Holly introduces today's topic: how parents and caregivers can help children and teens with eosinophilic disorders build the skills and confidence they need to manage their health as they grow and navigate transitions from pediatric to adult care teams.   [2:06] Holly introduces and welcomes today's guest, Dr. Timothy Buckey, an allergist and immunologist at the University of Pennsylvania and the Children's Hospital of Philadelphia.   [2:14] Dr. Buckey's research interests include eosinophilic esophagitis, food allergy, medical ethics, and improving access to medical care for vulnerable populations.   [2:24] Dr. Buckey thanks Ryan and Holly for having him on the program. He's a long-time listener and is looking forward to the conversation on this important topic.   [2:32] Holly comments on Dr. Buckey working with children and adults. Dr. Buckey says he sees patients of all ages, from a few days old at the Children's Hospital through the end of life at the adult hospital. He loves that there's no patient he cannot see.   [3:10] Dr. Buckey says, in addition to seeing patients as an allergist/immunologist, he is also a medical ethicist or bioethicist. He is trained in medical ethics, and he utilizes that approach in shared decision-making, trying to understand his patients' goals and values for their health, and making a plan that works for them.   [3:31] Holly says her allergist/immunologist at Massachusetts General also sees teens and adults.    [3:53] Dr. Buckey says a special aspect of the relationship he has with his patients is that he has been in a fairly similar position, as someone who has dealt with many different allergic or atopic conditions for his whole life.   [4:08] Dr. Buckey says his conditions started with asthma as a young child, which he still manages, allergic rhinitis, and environmental allergies. He has been on allergy shots. He deals with atopic dermatitis, or eczema. He has seen an allergist/immunologist his whole life. It feels like full circle to be one now.   [4:29] Ryan feels like it's easier from a patient perspective if your physician gets it and can understand what you're going through.   [4:41] Ryan says that eosinophilic disorders generally require lifelong management, especially when diagnosed in children. Over time, a patient may need to transition from being treated by a pediatric care team to an adult care team.   [4:57] Ryan says that Dr. Buckey, through his work with the University of Pennsylvania, provides a lot of support for young adults going through that transition. Ryan asks Dr. Buckey to explain the importance of transition of care.   [5:14] Dr. Buckey breaks down the term into its two words: transition and care.   [5:24] Transition of care is a process in which we are shifting from a pediatric health model, in which a parent or guardian is the primary historian, or person managing the patient's care, to one in which the patient becomes the primary point of contact.   [5:49] Dr. Buckey says that during this process, our overarching goal is for an individual to begin to develop ownership of their health so that they can take care of their medications, schedule appointments, and know their bodies.   [6:05] Dr. Buckey says the second part is care. Not only medical care, but it is a period of life of going through a lot of personal growth. Dr. Buckey's goal is for patients to know themselves and learn to support themselves as independent individuals.   [6:30] Holly appreciates that Dr. Buckey talked about the transition at that age when there are so many things going on with becoming an adult.   [6:40] Holly says when she worked at the Children's Hospital of Colorado, we thought about this a lot.   [7:00] Holly said that when she interacted with patients, she tried to look at them, even if they were little. If they were three or four, she asked them what their favorite foods were.   [7:17] Holly says she was trying, as young as possible, to have them feel that they have some say and control over their health, and they can start developing how to be a historian of their medical journey.   [7:36] Dr. Buckey says every person matures or develops at different times. Having a strict age cutoff may ignore the unique aspects of each person and their history. Dr. Buckey generally begins that conversation in the teenage years through the early 20s.   [8:02] Dr. Buckey says that with some kids, he will introduce the idea earlier than a teenager, based on how much they understand about their health. As they start to switch to adult care, he emphasizes that the transition process is not over at their first adult visit.   [8:24] Dr. Buckey says it takes additional visits for that person to understand themselves, to know how to request a refill of their medication, to know how to make the appointment, and to know how to contact Dr. Buckey if they have questions.    [8:38] Dr. Buckey says it is a continual process, and it doesn't just stop at that first visit with an adult doctor.   [8:45] Holly agrees that people reach maturity at different ages. Holly remembers that when she was in college, she asked her mom to schedule her dentist and doctor appointments.    [9:17] Dr. Buckey says it's overwhelming and it can be quite scary. It takes a team.   [9:30] Holly notes there are age ranges on the Healthcare Transition Timeline Toolkit for what the provider should be doing to help the patient get ready for transition, and what the caregiver and the patient should be doing. She invites listeners to check it out at eoscare.apfed.org.   [9:45] Holly asks about ages when a child would meet alone with their physician for part of the appointment to talk about things they don't want to say in front of their parent.   [10:18] Dr. Buckey says it depends on age and individual factors. He says he has met some very mature 10-year-olds and some not-as-mature 17-year-olds.   [10:38] Dr. Buckey says he understands how it might be nerve-wracking for parents to ask them to step out, but it is an important part of that person starting to know their own body.   [10:50] Dr. Buckey says if he's seeing an individual with asthma, he will have the parents step out briefly from the clinic room so he can have a conversation about possible triggers they may not be comfortable talking to their parents about, such as vaping or cigarette use, and if they have tried them or friends have tried them.   [11:20] Dr. Buckey says they will discuss that, and that's not something they always feel comfortable sharing with their parents because they feel like they may be disappointing them. The doctor needs to know it to keep them healthy.   [11:44] Holly says in her practice, a lot of teenagers will ask to meet with her if they have IgE-mediated food allergies on top of eosinophilic-related disease.   [11:51] They want to know if it's safe to kiss a person if they've eaten this or what to do to protect themselves. If they get this symptom, what should they do? They feel comfortable asking Holly. She's trying to coach them to feel confident in their bodies.   [12:22] Ryan comments that he's gone through the transition of care process relatively recently. The conversation has touched on so many things he remembers from the last 10 years of trying to transition.   [12:28] Even before that, at eight or nine, when the doctor asked what medications Ryan was on, his mother looked at him and said, You should know this; you take them every day. What medications are you on?   [12:43] Ryan says that was super helpful to him, as a young patient, that his parents supported him in making sure he was aware of his health, his treatment options, and was able to guide his own medical appointments, with supervision.   [12:57] Ryan had had no idea that he was choking on food or taking extra time to chew. It felt normal, so it was helpful to have a caregiver in the office. His caregiver would say it takes him half an hour to have a handful of crackers. That should not be happening.   [13:20] Ryan asked about caregivers helping with appointment management and prescription management. Until recently, Ryan's parents helped him.    [13:50] Ryan says, even into your 20s, that transition process is still happening. Ryan asks Dr. Buckey for advice on teens and young adults making their own appointments and dealing with healthcare systems.   [14:04] Dr. Buckey says it's difficult to navigate our healthcare system. There are questions about insurance and what is in-network vs. out-of-network. How do you get prescriptions filled? What's covered? Cost? So it's complicated.   [14:21] Dr. Buckey emphasizes that when we're talking about this transition process, sometimes a part can get misconstrued: that we don't want parents or caregivers involved. We do.   [14:35] Dr. Buckey says his goal is for people to have the community, however they define that, to still be a part of their healthcare. What he is aiming for with this transition is that the individual starts to take control of their own health.   [14:50] If making appointments is something they still need some help from their parents, that is them recognizing what they need. [14:57] If they want to come to the visit but have Mom or Dad or their significant other on the phone, because that is the support that they need, then absolutely do that.    [15:08] Dr. Buckey says, as we are generally switching over, at 18 into our early 20s, recognizing the support you need is an important part of knowing your own body.   [15:20] Holly says that's an important stage, and she got there later. She needed help when she was younger; then, in her teens, she said, "No, I've got it." Now, in her 40s, she would like some help again.   [15:37] Holly says it's OK to ask for help when you're feeling overwhelmed, and you can't navigate all these chronic diseases on your own.   [15:42] Ryan says this is a topic we're both passionate about. At APFED, we see younger patients stop seeing their care team when they get to their college years.   [15:54] Ryan says part of it is they get busy and are not able to engage with the patient advocacy community as much, and part of it is they drop out of care. It's important to have caregivers or your community to support you through that process.   [16:07] Ryan says, whatever it takes to stay in care and make sure you're healthy is super important.   [16:14] Ryan brings up legal age cutoffs. In his 20s, he has access to his medical records; his parents don't. He still wants their take on some stuff. After he gets an endoscopy, he pulls up MyChart to show his parents his results.   [16:38] Dr. Buckey says once we turn 18, we are legally adults. At that point, the patient is the owner of their health and their information. They have to provide access to their parents to be able to see it. That can be done in several different ways.   [16:55] If you have an electronic health record, sometimes you can add a proxy, or you can just pull up the results and choose to show your parents.   [17:05] Dr. Buckey says if he is seeing an 18-, 19-, or 20-year-old at the Children's Hospital, he will tell them that once they turn 18, he only communicates results to them.   [17:16] Of course, they can have their parents, caregiver, or significant other present. That is their choice to invite them into that conversation. That is very helpful for many people.   [17:30] Dr. Buckey is a proxy for his parents. Holly is also a proxy for her parents.   [17:41] Holly says that having somebody who is in your corner to talk about your results with and talk about the next stages of treatment is always important because it can be overwhelming.   [17:51] Dr. Buckey gives kudos to pediatric providers. They are so wonderful, and they build such a great relationship that it makes it hard for us to want to leave.   [18:03] When Dr. Buckey was at the point of applying to medical school, his pediatrician told him they needed to have him see an adult doctor. He was reluctant to transition. His pediatrician inspired Dr. Buckey to go into medicine.   [18:25] Ryan says it can be a hard transition, with so much else going on that you want to stay in that familiar environment.   [18:31] Ryan shares how he recently dealt with transitioning insurance plans.   [18:55] Dr. Buckey says the general rule is that you can stay on your parents' health insurance until you are 26. There are caveats for individual persons and individual insurance plans.   [19:05] Some people start working and may get health insurance through their job, so you may have your own health insurance at 18 and no longer be on your parents' insurance.   [19:16] When you're 16 or 17, it's an important time to talk to your parents, or whoever's insurance you are on, about what's going to happen when you turn 18.   [19:26] Ryan says it's specific to each medical plan. He says when he went to college, he was offered a student health insurance plan, but his specialty medications, like biologics, were not covered, only hospitalizations.   [20:00] Ryan says it's always good to double-check what your plan options are and what those plans cover, to make sure that you're able to maintain the care you need.   [20:12] Holly says that something really helpful is to sit down with the family and help them identify an adult care team that will fit them best as they transition.   [20:33] Dr. Buckey says sitting down and having that conversation is an important part of the visit. Talk to patients about where they will live. If you're living away at college or moving away for a job, what geographic area are you moving to?   [20:53] If you're going to be on a different coast or city, do you want to switch your care over to that area? Or do you want to keep your care in the area where your parents live and come back during your breaks and see your physician?   [21:09] Dr. Buckey says it's also important to have a local provider to go to if something comes up. Talk to your pediatric provider about whether they know adult clinicians who care for the condition that you have in the area where you will be living.   [21:30] Dr. Buckey says another important thing to think about is,  when we are in pediatric care, we are often follow-up or return patients. Visits may be of a different duration. Sometimes it's easier to schedule a follow-up visit than a new patient visit.   [21:48] Planning that new patient visit in your new area, sometimes weeks or months ahead, is an important part of this transition process to ensure that there are no gaps in the care you're going to be having.   [22:08] Holly mentions the APFED Specialist Finder on the APFED website. It's a tool for when you are not part of a multidisciplinary setting or wherever you're going, no one knows who they would recommend in that part of the country.   [22:25] There are a lot of good people listed on the APFED Specialist Finder if you are going to be moving somewhere else or getting your care in another place. Dr. Buckey proudly shared that he is on that Specialist Finder. So is Holly.   [22:51] Ryan recently moved to California, and he is trying to find care teams there that specialize in EoE.   [23:12] Ryan asks if patients transitioning to a new doctor typically need a referral from their existing physician, or do you chat with your insurance company first to help find new care teams?   [23:25] Dr. Buckey says some insurance policies do require a referral for each visit you are going to have with your provider. For many policies, you can look online to see who is in-network vs. out-of-network.   [23:52] Sometimes there are different costs to see someone who is in-network vs. out-of-network. The differences can be dramatic. Discuss it with your physician or clinician, but also with your insurance company.   [24:13] Dr. Buckey says make sure there's no lapse in care. We don't want someone to go without their medication. If you're no longer seeing your pediatric provider, make plans to see an adult provider who can continue your prescriptions.   [24:45] Ryan says we see a lot of patients who have an EGID and also other conditions. We see a lot of comorbidities within our community. We have multiple things going on, which can make this transition process especially complicated.   [25:15] Dr. Buckey says many people are experiencing different things and may need to see more than one clinician. They probably also have a primary care doctor. They are going to have to switch from each of those clinicians to an adult provider.   [25:38] That transition takes time and effort. It can sometimes be a long wait. Beginning that process early will only set you up for success. Dr. Buckey says different health systems will accept different insurances.   [26:01] Dr. Buckey says sometimes for specialty medicines, when you switch health systems, the specialty medication may be provided by a different specialty pharmacy than it was when you were seeing a pediatric healthcare team.   [26:13] How you schedule appointments, how you speak to someone if you're having new symptoms, all changes as you're switching to adult care. Dr. Buckey says because this is complicated, we do worry that sometimes things can get lost during the transition.   [26:37] Planning will only set you up for success, so that nothing gets missed in the switchover process; you have no lapse in medications or procedures that you need, and you can continue to see the clinicians you need to keep you healthy for your best life.   [27:03] Holly has learned from her healthcare and working in different hospitals to ask, before picking a specialist, what electronic medical records (EMR) the practice uses. Some can communicate with each other, and it makes the transition smoother.   [27:25] Holly says some places have EMRs that don't communicate with other places, and that makes sharing information tricky. Holly has experience dealing with EMRs that do not talk to each other at all.   [28:05] Dr. Buckey says if you use an EMR that communicates with others, your care can easily be accessed at different institutions. Dr. Buckey explains how that helps make the transition smooth if transferring to adult care or switching healthcare systems.   [28:56] Dr. Buckey says things you need for a helpful transition are to know your medical history, your diagnoses and how they were made, your current medications and dosing, and medications or therapies you tried before that weren't successful for you.   [29:31] Dr. Buckey says, as we approach the era of precision medicine where we are treating each person in a different way, knowing what did or did not work for you is so helpful for your clinician so they can continue to help you feel good.   [29:49] Holly suggests a role-play. For example, if she's going to see Dr. Buckey with her records from Maine, which do not communicate with his EMR. What should she physically bring to the visit?   [30:23] Dr. Buckey says to know what health conditions she is being treated for. In Holly's case, they will talk about asthma and EoE.   [30:33] Dr. Buckey would like to know if Holly has ever been hospitalized for asthma, what inhalers she takes, what inhalers she tried before, and if she is on any biologic medicines, the doses and the frequency, and what she tried in the past.   [30:53] Dr. Buckey would ask if she's ever had breathing tests, called spirometry or pulmonary function tests.   [30:58] Having paper copies is wonderful. You can bring them in, and he will review them at the visit. Dr. Buckey always appreciates it when patients send them to him ahead of time, so he can review them and prepare for a successful first visit for both of them.   [31:18] Dr. Buckey says if we're talking about EoE, he will ask when the diagnosis was made, what symptoms led her or her parents to do that first endoscopy or see an allergist, immunologist, or gastroenterologist, when the most recent endoscopy was, and what medications she was on when she had her different endoscopies.   [31:40] Dr. Buckey says usually clinicians are keeping track of this, so Holly could ask them for copies of procedures she has had, the last two or three office visits, which are usually pretty comprehensive, and a list of any medications Holly takes.   [32:00] Holly appreciates having the ability to send paper records in advance. When Holly sets an appointment, she will fax Dr. Buckey some of her tests and important facts to look at before her appointment.   [32:20] Holly says some places won't look at the reports in advance, so she brings a bullet list with her of all the things Dr. Buckey listed for them to look at when she checks in to the appointment.   [32:39] Dr. Buckey responds that healthcare is very busy and some clinicians don't have the time to look at reports ahead of the visit, but can take five or ten minutes to look at them at the start of the visit to be successful and have a comprehensive visit.   [32:59] Ryan appreciates Holly's point to bring a bulleted list to the visit. Ryan is grateful that his parents kept his records organized throughout his life. For any caregivers listening, set your patients up for success by keeping track of these things over time.   [33:24] Ryan has a one-page summary he gives to all new providers of all his hospitalizations over the last 20 years, the medications he has been on, with date ranges, his diagnoses with dates, and different procedures and endoscopies.   [33:46] Ryan says that one-page summary is in 6-point font to squish it down to one page. It's helpful to have all that information organized together.   [33:55] Ryan invites caregivers: If you have a young patient and you're starting to think about the transition process, start keeping track of all that if you haven't before.   [34:03] Dr. Buckey says our health can be complicated. We can have periods when we're feeling great and periods when we're having more symptoms. Having it written down is an easy way to keep track so things don't get forgotten or lost.   [34:22] Dr. Buckey often says he appreciates when patients come in with that sort of list of their history because it shows how invested you are in your health and keeping yourself healthy. It's a wonderful way that you can be proactive.   [34:40] Ryan says it can feel like a big undertaking if you start now and you're in your 20s. Whenever you can start keeping track of how you're feeling and why, what treatment and symptoms you're having, it's good to have more information than less.   [34:58] Dr. Buckey says there's never a period when it's too late. If you are in your 30s or 40s and just starting out, it's very helpful. The provider can prompt you with questions that will help you recall things you had in the past and add them to the document.   [35:21] Ryan says it's a very collaborative process. Discuss it with your clinician, who may point out symptoms you should note.   [35:40] Ryan asks, when you are transitioning from pediatric to adult care, is it typical for an adult care provider to call a pediatric care provider with questions? Dr. Buckey says in his system, doctors have those conversations, which is a great asset to patients.   [36:33] Dr. Buckey says, for example, if I were not their pediatric allergist, but I would become their adult allergist, I would reach out to their pediatric allergist and ask details about their history. I would also reach out to their dermatologist and gastroenterologist.   [36:59] It's helpful to ask each other questions, know things to look out for, or things in a person's history that might be helpful as therapies and medications continue to advance that might be a good fit. It helps us to have a good comprehensive plan in place.   [37:26] Dr. Buckey says talking to each other helps to provide good longitudinal care.    [37:39] Ryan asks about having procedures and allergy testing in a pediatric setting and switching to a new provider. Do adult providers typically want to repeat testing?   [38:04] Dr. Buckey says it will depend on each person, when they were performed, and what was performed. If Dr. Buckey is seeing someone for food allergies, was skin or blood testing done last year or 10 or 20 years ago? Last year is pretty current. If it was 20 years ago and you're 22, your body is very different from when you were two.   [38:40] Dr. Buckey says if you have asthma and you had a breathing test two weeks ago, that's very recent. If you have not had a breathing test done in 10 years, I probably would repeat it on your first or second visit.   [38:56] Dr. Buckey says, for endoscopies, if you have EoE of another EGID, it would depend on timing. Was this done recently or in the remote past? Was it done on the current regimen you are on? Was it done on a different regimen?   [39:14] Dr. Buckey says I'm going to ask you if you're having any changes in symptoms recently. If anything has changed how you're feeling, it's probably going to prompt me to do a new set of testing and not just rely on the ones you had before.   [39:31] Dr. Buckey says, if you could bring the previous tests to me, I can compare. I can see what your endoscopy looks like now vs. two years ago. It's helpful to have that baseline to compare to.   [39:48] Dr. Buckey adds that knowing how you're feeling, or what's been done before, or your medical history, helps clinicians to take care of you as best we can.   [40:15] Holly says this is such a needed conversation. It will be helpful for our listeners, both practicing physicians and patients.   [40:37] Holly asks what advice Dr. Buckey gives for navigating challenges during the transition of care.   [40:51] Dr. Buckey says for every new EoE patient visit, he shares a link to the APFED website because there are such wonderful resources and references there. He explains to them what APFED is, and he provides resources to other websites or research that he thinks is helpful for them, depending on what each person is looking for.   [41:31] Talking with your doctor about what you are looking for is very helpful.   [41:38] In terms of the transition process, it's an exciting period. We're often going through a lot of big life changes. It could be our first time living away from our parents, having a job, or going to college.   [42:05] Know your own health. Learn about your body. We are the best advocates for ourselves. Only you know what you are feeling. Only you can tell your doctor what you're feeling. Taking ownership of your health will set you up for success for a healthy, long life, achieving your goals. Holly says that sums it up beautifully.    [42:40] Holly says for listeners who are feeling overwhelmed, unsure, or want to find out more about the transition, eoscare.apfed.org is a great site that helps you navigate healthcare for eosinophilic conditions. It also has a tab for building a care team.   [43:05] Ryan says it's great when the guest plugs APFED resources! For those who are looking to learn more about transition of care, please visit apfed.org and check out the links in the show notes below.   [43:25] If you're looking to find specialists, as you're going through this transition process, who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder, available at apfed.org/specialist.   [43:36] If you would like to hear some recent sessions from the 24th annual Eos Connection conference, we had a session focused on transition of care. Those are available on demand online.    [43:50] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [44:00] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experiences, please check out apfed.org/shareyourstory.   [44:09] Ryan thanks Dr. Buckey for joining us today. It was such a great conversation. This will be so helpful for the community. Dr. Buckey says the work of this podcast and of APFED as a whole is so important.   [44:36] Dr. Buckey thanks all the patients and colleagues that he has. He has a job where he walks with a smile on his face every day. It's a privilege to take care of his patients and work with his colleagues. Thank you all for listening today.   [44:56] Holly thanks APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.orgapfed.org/specialist apfed.org/connections eoscare.apfed.org Eos Connection 2026 Timothy Buckey, MD, MBE Hospital of the University of Pennsylvania Children's Hospital of Philadelphia Department of Medical Ethics and Health Policy Healthcare Transition Timeline Toolkit Education Partners: This episode of APFED's podcast is brought to you thanks to the support of AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   Tweetables (Edited):   "I am trained in medical ethics, and I utilize that approach, particularly in shared decision-making, trying to understand my patients' goals and values for their health, … and making a plan that works for them." — Timothy Buckey, MD, MBE   "During this [transition] process, our overarching goal is for an individual to begin to develop ownership of their health so that they can take care of their medications, schedule appointments, and know their bodies." — Timothy Buckey, MD, MBE   "Having a strict age cutoff may ignore the unique aspects of each person and their history. I generally begin that conversation [about transition of care] in the teenage years through the early 20s." — Timothy Buckey, MD, MBE   "Healthcare is very busy, and some clinicians don't have the time to look [at reports] ahead of time, but often, we can take five or ten minutes to look at them at the start of the visit … to be successful and have a comprehensive visit." — Timothy Buckey, MD, MBE   "We are the best advocates for ourselves. Only you know what you are feeling inside. Only you can tell your doctor what you're feeling. Taking ownership of your health will set you up for success for a healthy long life, achieving your goals." — Timothy Buckey, MD, MBE   Guest Bio: Timothy Buckey, MD, MBE, is an allergy and immunology attending physician with a joint faculty position at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, and a secondary academic appointment in the Department of Medical Ethics and Health Policy. Dr. Buckey completed his allergy and immunology fellowship training at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. He attended Georgetown University School of Medicine. He also received a Master of Bioethics from the Perelman School of Medicine at the University of Pennsylvania.   Several of Dr. Buckey's research interests include eosinophilic esophagitis, food allergy, medical ethics, and improving access to medical care for vulnerable populations. He was the lead author on one of the largest studies evaluating the rate of eosinophilic esophagitis during food allergy oral immunotherapy. Dr. Buckey was also the lead author on the pivotal 2024 food allergy study, which utilized allergist-performed oral food challenges to demonstrate there are no differences in food allergy outcomes based on race or ethnicity. Dr Buckey has also become a pioneer in investigating the intersection of medical ethics with allergy and immunology. Dr. Buckey developed the first comprehensive ethical framework for the specialty of allergy and immunology to assist clinicians with navigating ethically complex decisions in their clinical practices. He utilizes this patient-centered approach in the clinic when caring for patients with allergic and immunologic conditions of all ages.   Website profile: pennmedicine.org/providers/timothy-buckey

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater. In this week’s episode of "The Top Line," Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron share their takeaways from another whirlwind season of earnings calls. Alongside a Q2 scorecard breakdown, the Fierce editors discuss how several new CEOs are finding their footing, which drugs appear poised to cross the $1 billion sales threshold in 2026 and more. To learn more about the topics in this episode: Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow Sarepta’s new CEO Michael Severino faces critical milestones to prove growth See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of updates that underscore the dynamism and complexity of these industries, marked by breakthroughs, strategic shifts, and regulatory hurdles. A notable scientific advancement comes from Biokin Pharma, where their bispecific antibody-drug conjugate, Iza-Bren, has achieved its primary endpoint in a Phase 3 trial focused on lung cancer. This success underscores the promise of ADCs in oncology, particularly their ability to target cancer cells while minimizing damage to healthy tissues. This approach not only enhances the efficacy of cancer therapies but also reduces side effects, providing a compelling argument for Bristol Myers Squibb's global testing initiatives in this domain. Such advancements are pivotal as they represent a significant leap toward more personalized cancer treatments. In regulatory and corporate news, Sanofi's recent restructuring following its acquisition of Blueprint Medicines has been significant. The integration process involves laying off 229 employees and closing operations in Cambridge. This move highlights a broader trend of consolidation within the biotech sector as companies seek to streamline operations and optimize resources amid an increasingly competitive market. Meanwhile, CSL Behring, an Australian company specializing in plasma and vaccines, anticipates mid-single-digit growth by fiscal year 2027. This optimistic outlook follows a period of challenges, including impairments and leadership changes. The company attributes its recovery largely to advancements in immunoglobulin therapies, which play a critical role in treating immune deficiencies and autoimmune diseases, highlighting the importance of innovation in sustaining growth. On the clinical trial front, Amylyx Pharmaceuticals is making waves with its GLP-1 receptor antagonist Avexitide. The drug has shown promising Phase 3 results by significantly reducing hypoglycemic episodes in patients with a rare endocrine disorder. This finding could revolutionize treatment protocols for endocrine disorders beyond traditional diabetes management, emphasizing the potential of GLP-1 inhibitors to enhance patient outcomes across various conditions. The latest updates from Amylyx Pharmaceuticals further showcase these industry dynamics as they prepare for an FDA filing for Avexitide following successful trial outcomes. The drug addresses post-bariatric hypoglycemia—a critical gap in metabolic disorder management—highlighting its potential impact on patient care and market dynamics with an anticipated $1.7 billion peak sales forecast. However, not all developments have been positive. EyePoint Pharmaceuticals faced setbacks with Duravyu, their AMD drug-device combo, which did not meet expectations in a Phase 3 trial. This highlights the inherent risks of developing drug-device combinations in late-stage trials and underscores the competitive pressures from market leaders like Eylea. In another strategic shift within big pharma, Merck KGaA has laid off 20 staff members from its U.S. research team as part of an ongoing reassessment of research priorities and resource allocations. Similarly, BioMarin Pharmaceutical's $275 million acquisition of Alesta Therapeutics marks an effort to bolster their bone disease portfolio and challenge competitors like AstraZeneca in specialized therapeutic areas. BioMarin's acquisition emphasizes competition within rare diseases—a sector ripe with opportunities for innovative treatments addressing unmet needs. Technological advancements are also reshaping the landscape. Johnson & Johnson MedTech's recent software updates for its Monarch bronchoscopy robot illustrate how digital solutions are enhancing diagnostic capabilities in lung cancer detection. This aligns with industry trends towards leveraging AI and robotics to improve precision medicine. Eurofins CDMO Alphora's expansion to meet the growing demand for high-potency active pharmaceutical ingredients reflects a rising interest in targeted therapies requiring precise dosing and specialized manufacturing processes. Such trends indicate a shift toward more personalized medicine approaches that prioritize efficacy and safety. Despite setbacks faced by companies like Regeneron due to safety concerns halting clinical trials, strategic moves such as GSK's licensing agreement with Chugai Pharmaceutical for an anti-dengue antibody exemplify ongoing efforts to combat infectious diseases through innovative biologics. The collaboration between Evaxion and Duke University on AI-designed glioblastoma vaccines further illustrates how artificial intelligence is becoming integral to next-generation cancer therapies—potentially paving the way for personalized vaccines that optimize antigen selection based on individual tumor profiles. Rigel Pharmaceuticals' launch of Veppanu marks another milestone—the first FDA-approved PROTAC for advanced breast cancer—demonstrating novel mechanisms targeting pathogenic proteins effectively while offering new treatment avenues for molecularly defined cancers. These stories capture the essence of today's pharmaceutical landscape: one where innovation coexists with challenges but holds immense potential to transform healthcare delivery globally. As companies continue pushing boundaries with emerging technologies like AI integration or expanding into niche markets through strategic acquisitions—the future looks promising for delivering more targeted solutions tailored toward specific patient populations worldwide.Support the show

Wayne brings 25+ years in senior leadership roles, culminating with two assignments as President for the APAC region in publicMNCs with healthcare focus (CooperVision, GN Hearing). ​His substantial service in the prescription pharmaceutical industry culminated with senior leadership roles at Sanofi and Janssen-Cilag (J&J). He has led teams of up to 600 direct employees, and revenues of up to US$600m. Businesses under Wayne's leadership have delivered exceptionally strong returns with fast revenue growth and market share gains. ​Wayne has deep experience throughout the APAC region, having been in APAC leadership roles since 2006. He has lived and worked in both China and Singapore, and now operates from Singapore and Sydney. He has had significant exposure to the Boards of public MNCs as well as serving as a member of Global Leadership Teams.​Wayne is degree qualified in both Law and Commerce / Marketing from UNSW. He has previously founded and ran his own business, during which he delivered comprehensive leadership programs to a multitude of large and diverse businesses in both Australia and Asia including National Australia Bank, Sanofi and Schering-Plough. He is DiSC certified, has a Cert IV in Workplaceand Business Coaching and is a member of the ICF. He is an avid world adventure traveller, marathon runner (10 completed marathons) and has studied and performed in improvised theatre.​After exiting the corporate world mid 2022, Wayne founded engage4performance Pty Ltd where he combined long held passions (executive coaching and development, speaking) with new endeavours including podcasting (Hard Yards in Leadership) and writing (4 short leaderships books thus far and more on the way). He also is an avid volunteer with Asia Mentors Circle where he devotes significant time to mentoring Asian leaders toward global senior roles.​ Hosted on Acast. See acast.com/privacy for more information.

Guest Full Name: Dr. David-Alexandre (“DA”) C. Gros, MD CEODA's Bio:Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and is currently the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935.Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.Company: Eledon Pharmaceuticals, Inc.Ticker: ELDNWebsite: https://eledon.com/About the Company:Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.

Caroline Nogueras va vous raconter une affaire encore non élucidée à ce jour. En octobre 2005, quand Eric Boisseranc rentre chez lui à Chazay d'Azergue tout près de Lyon, il découvre sa fille Marine allongée derrière le canapé, morte de plusieurs coups de couteau… Dans le dernier épisode de cette saison, Caroline Nogueras reçoit Eric, le père de la victime, qui se bat toujours pour retrouver le meurtrier et faire justice à sa fille. Le sans-abri ou l'amoureux éconduit ? Octobre 2006. Cela fait un an que Marine a été tuée. Des agents de police lyonnais viennent de contrôler un sans-abri qui a un mandat de recherche sur le dos… ça peut les intéresser... Les gendarmes de la cellule d'enquête se précipitent au 3 rue du Père Chevrier, un centre pour SDF. Dans le casier du gars, ils trouvent : des vêtements de femme, un pantalon tâché de sang… et une sacoche du laboratoire Sanofi — le laboratoire pour lequel travaille Éric Boisseranc. Il n'y a pas l'ombre d'un doute : cette fois, nous tenons notre coupable ! Un podcast Bababam Originals Voix : Caroline Nogueras Ecriture : Tiphaine Pioger Learn more about your ad choices. Visit megaphone.fm/adchoices

A gripe afeta cerca de 1 bilhão de pessoas por ano em todo o mundo. Mas seus efeitos podem ir além dos sintomas imediatos, como febre, dor no corpo, cansaço, tosse, nariz entupido e calafrios.A doença também pode provocar consequências menos conhecidas, como risco aumentado de ataque cardíaco e AVC.Neste episódio do DrauzioCast, Drauzio Varella conversa com o cardiologista Múcio Tavares sobre a relação entre gripe e saúde cardiovascular e a importância da vacinação no longo prazo.Conteúdo produzido em parceria com Sanofi.MMAT-BR-2602634Veja também: Por que o Brasil ainda luta para atingir a meta de vacinação contra a gripe?

On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: https://diabetes-connections.com/events/   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com   Transcript:  (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can't wait to tell you about Cookie Queens.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you're organizing: a fundraiser, walk, or local meetup Products you've created: maybe you've written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It's your chance to share what you're doing and help others get connected! Full instructions are on the website. While you're there please check out our events. We're turning toward fall and we have a lot going on – MNO and Club 1921.   Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It's my show and I can't wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don't mention it in the trailer, but you can see her omnipod. Here's a clip:   Start the very beginning and stop after "I want to be a supreme court justice." (stop after the "oh..laughter" https://www.youtube.com/watch?v=nnSQS43Eil8   Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she's selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. "if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It's just that sweet." Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer:   XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it's experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug's safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time.   The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values.   The device needs further validation in diverse clinical settings and across large diabetic cohorts.   https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx   XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level < 3.9 mmol/L (70 mg/dL). The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C.   https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members' patience while a report is prepared.   The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges "an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care," an ADA scientific journal.   https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox..   XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years. These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women) Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems. And while the study says it's 37% higher for the younger group, the actual rate was still very low. As always, I'll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2.   https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir XX Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life. https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx XX Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year. https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/ XX The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program. Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes. The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress. The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions. https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/ XX Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump. Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott's dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year. Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month. https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/ XX Eli Lilly expands it's partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply XX Alex Cooper – the host of the top podcast Call her Daddy – announced she's been diagnosed with gestational diabetes.   "When I got this diagnosis, the first couple days, I was really hard on myself," the 31-year-old admitted. "It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it's me on an island." She says she found an online community that's been helping. In sharing her experience, she hoped it would alleviate the stress. https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis XX Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes. Check out all the charities and vote for your favorites – you've heard of so many of these I promise – at the link in the episode show notes, . https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact

¿Qué pueden tener en común el eczema de un bebé, el asma de un niño en edad escolar y la dificultad para tragar de un adolescente? Aunque parecen enfermedades completamente diferentes, pueden compartir un mismo motor inflamatorio: la inflamación tipo 2. Lo que vemos en la piel, los pulmones o el esófago puede ser solamente la punta del iceberg. Hoy abordamos lo que ocurre debajo de la superficie y de cómo esta inflamación puede afectar no solo la salud del niño, sino también su sueño, crecimiento, aprendizaje, bienestar emocional y vida familiar. Con este episodio iniciamos la sexta temporada y comenzamos una serie especial de cinco episodios, patrocinada por Sanofi, en la que vamos a conversar sobre la inflamación tipo 2 y su relación con diferentes enfermedades inflamatorias. Nuestra productora Vanessa Bernal, entrevista a la anfitriona del podcast Pediatras en Línea, la doctora Carla Torres-Zegarra, quien nos ayudará a entender estos temas de manera práctica, clara y basada en evidencia. La Dra. Carla Torres-Zegarra es dermatóloga pediatra, pediatra y dermatóloga, con triple certificación de especialidad. Se graduó de Medicina en la Universidad Peruana Cayetano Heredia en Lima-Perú, realizó su residencia de Pediatría y jefatura de residentes en Cleveland Clinic en Ohio-USA, y completó su formación en Dermatología y la subespecialidad en Dermatología Pediátrica en la Universidad de Colorado y Children's Hospital Colorado en Colorado-USA. Actualmente es profesora asociada en la Universidad de Colorado, dermatóloga pediatra en Children's Hospital Colorado y directora del programa de subespecialidad en Dermatología Pediátrica. Además, es creadora y conductora de Pediatras en Línea y se dedica a compartir información médica en español, clara y basada en evidencia. Este episodio cuenta con el patrocinio educativo de Sanofi. La información que compartiremos tiene fines educativos y no reemplaza la evaluación médica individualizada. Instagram: @dra.carlatorresz ¿Tienes algún comentario sobre este episodio o sugerencias de temas para un futuro podcast? Escríbenos a pediatrasenlinea@childrenscolorado.org.